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Purpose. We introduced a new concept of ex vivo gene expression analysis (Mitsuhashi, Clin Chem
53:148–149, 2007), where drug action was simulated under physiological conditions. This model system
was applied to study various fields of drug development.
Materials and Methods. Heparinized human whole blood was incubated with drugs for less than 4h. The
changes of specific mRNAwere then quantified using the method we developed (Mitsuhashi, Tomozawa,
Endo, and Shinagawa, Clin Chem 52:634–642, 2006).
Results. The mRNA quantitation method was used as a model system to study the following areas: (1)
identification of respondents and non-respondents, (2) ex vivo compound screening, (3) determination of
individually optimized doses, (4) drug-to-drug comparison, (5) assessment of leukocyte toxicity, (6)
discovery of molecular targets, (7) assessment of the action of dietary supplements, and (8)
characterization of respondents and non-respondents for various dietary supplements.
Conclusion. Since ex vivo assays are safe, a large number of healthy donors and disease patients can be
recruited to identify individual-to-individual variations, which is not available from current preclinical
study models. Although each system should be validated using a large number of samples, the ex vivo
analysis will be a new tool for the development of drugs and dietary supplements in future.
KEY WORDS: blood; dietary supplement; drug development; gene expression; mRNA.
INTRODUCTION
Drug candidates are usually selected by various cell-
free systems followed by a series of experiments with
cultured cells and experimental animals. The final one then
moves to clinical trials. However, because of the gap
between these preclinical study models and the human
body, many drug candidates fail during clinical trials. Some
drugs are very effective in cultured cells or animal models,
but fail to show any efficacy in humans. Moreover,
unexpected severe side effects may happen only in human.
Since the clinical trials are extremely expensive and have a
potential for life-threatening adverse reactions, the improve-
ment in preclinical studies is clearly one of the main
priorities of pharmaceutical research.
Although early stage drug candidates cannot be admin-
istered to humans, it is technically and ethically feasible to
mix these drugs in human whole blood to evaluate the
efficacy and toxicity. It is particularly reasonable if such drugs
are planned to be administered intravenously or expected
blood levels are predetermined by mathematical models or
animal experiments. Because in vitro assays are safe, a large
number of healthy and disease donors can be recruited.
Unfortunately, such blood experiments do not analyze drug
actions on organs or whole body. However, it is at least useful
to identify the effect on leukocytes. Thus, the methodology is
primarily applicable to anti-inflammatory and immunomodu-
latory drugs. It may be useful for other drugs to assess
adverse effects on leukocytes, because leukocyte toxicity is
occasionally fatal. Moreover, leukocytes may be used as a
surrogate marker for various diseases.
Typically, mononuclear leukocytes areisolated from human
whole blood, suspended in culture media, incubated in a CO2
incubator for a couple of days to several days with drugs, and
various drug-related protein syntheses and biological functions
are determined. However, the assay condition is no longer
physiological due to a lack of communication among different
cell populations, oxygen supply from erythrocytes, as well as
complex interactions with plasma proteins and other compo-
nents. Secondary reactions may happen during the lengthy
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,6incubation period. In order to avoid these problems, our group
recently reported a novel assay system, in which human whole
blood was stimulated with appropriate drugs in vitro for less
than 4h, and drug-induced mRNA expression was quantified
(1,2). The use of whole blood and a short incubation period
are very physiological and considered as ex vivo.
Although the induction of mRNA does not always cor-
respond to protein synthesis and subsequent biological and
clinical outcomes due to altered splicing, post-translational
modification, co-activation of inhibitory cascades, etc., the
induction of appropriate mRNA under ex vivo condition in
each patient will be an interesting research model for drug
development. Especially, this ex vivo assay may become a
powerful tool for the analysis of individual-to-individual
variations, which is a foundation of tailored medicine, and
is difficult to assess by current preclinical studies. In order
to emphasize the value of ex vivo assay, various applications
are demonstrated in this study, although each system should
be validated clinically using appropriate drug targets.
MATERIALS AND METHODS
Materials
Anti-T cell receptor (TCR) monoclonal antibody (IgG1 κ),
control mouse IgG1 κ (BioLegend, San Diego, CA, USA), GSK-
3b inhibitor I, JNK inhibitor II, JAK inhibitor I, Aloisine A,
(Calbiochem, San Diego, CA, USA), fucoidan (Dr. Fucoidan
V-MAX, Ventuno, Fukuoka, Japan) were obtained from desig-
nated suppliers. Reagents for mRNA analysis were the same as
our previous publication (1). All other chemicals were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
Blood Sampling
Heparinized whole blood samples were obtained from
Apex Research Institute (Tustin, CA, USA), Hitachi, Ltd.,
Hitachi General Hospital (Hitachi, Japan), Cedars-Sinai
Medical Center (Los Angeles, CA, USA), and Salon de
Mediage Shirogane (Fukuoka, Japan) after respective Insti-
tutional Review Board (IRB) approvals. Blood samples were
stored at 4°C, and stimulated with appropriate drugs in the
same day of blood draw. After each drug treatment, blood
samples were stored frozen at −80°C.
Primers and Probes
Polymerase chain reaction (PCR) primers and TaqMan
probes were designed by Primer Express (Applied Biosystem,
Foster City, CA, USA) and HYBsimulator (RNAture, Irvine,
CA, USA) (3,4) (Supplemental Table 1). Oligonucleotides
were synthesized by IDT (Coralville, IA, USA), Tsukuba
Oligo Service (Tsukuba, Japan), Nippon EGT (Toyama,
Japan), and Hokkaido System Science (Sapporo, Japan).
Blood Stimulation
In eight-well strip microtubes, 1.2–1.4μl of 50× concen-
trations of drugs or controls [phosphate buffered saline (PBS)
or dimethysulfoxide (DMSO)] were added, and stored at
−20°C until use. About 60–70μl of blood samples was added
into each well in triplicate, and incubated at 37°C for 2–4h
with cap closed. In some experiments (Figs. 2, 3 and 8),
inhibitors were added 30min–1h prior to the stimulations.
After each treatment, 50μl of whole blood was transferred to
filterplates as described in the next section.
mRNA Quantification
The quantity of mRNA was determined by the method
we developed previously (1,2). In brief, 50μl of blood
samples were applied to 96-well filterplates to trap leuko-
cytes. Sixty microliters of lysis buffer containing a cocktail of
specific reverse primers was applied to the filterplates, and
the resultant cell lysates were transferred to oligo(dT)-
immobilized microplates (GenePlate, RNAture) (5,6)f o r
poly(A)
+ mRNA purification. The cDNA was directly
synthesized in 30μl solutions at each well: specific primer-
primed cDNA in the liquid phase and oligo(dT)-primed
cDNA in the solid phase (1). Four microliters of undiluted
(Figs. 1, 2, 3, 4, 5, 7 and 8) or diluted (Fig. 6) cDNA solution
was used for TaqMan PCR (Figs. 3, 4, 5 and 8)( 7) or SYBR
Green PCR (Figs. 1, 2, 6 and 7)( 8) using iTaqSYBR master
mix (BioRad, Hercules, CA, USA), as described previously
(1,2). Each gene was amplified individually. The cycle
threshold (Ct), which was the cycle of PCR to generate certain
amounts of PCR products (fluorescence), was determined using
analytical software (SDS, Applied Biosystems). In order to
maintain the assay specificity of SYBR Green PCR, 1× RT
buffer was used as negative controls to confirm no primer
dimer was generated under this PCR condition. Moreover, the
Fig. 1. T-cell receptor (TCR)-mediated TNFα mRNA expression in
human whole blood. A Fifty microliters of heparinized human whole
blood was stimulated in triplicate with various concentrations of anti-
TCR monoclonal antibody (filled circle) or control IgG (open circle)
for 2 h at 37°C. The TNFα mRNA was then quantified using
SYBRgreen PCR, and the fold increase was calculated using the
values of solvent (PBS) as control as described in “Materials and
Methods”. Each data point is the mean±standard deviation (SD)
from triplicate aliquots of whole blood. B Summary of 18 healthy
adult volunteers using 10 μg/ml each of anti-TCR or control IgG.
Because control IgG increased the levels of mRNA (A, open circle),
the fold increase was calculated using the values of the same
concentrations of control IgG in the subpanel B. Each data point is
the mean value from each individual.
1117 Ex Vivo Platform of Drug Developmentmelting curve was analyzed in each case to confirm that PCR
signals were derived from a single PCR product. We also
measured standard curves during PCR using known
concentrations (1–10
6 copies/well) of synthetic DNA
templates, and found that the efficiency of PCR was always
close to 100% under this PCR condition (annealing for 30s
plus extension for 1min) regardless of target species, because
tenfold differences of the amounts of templates were approx-
imately 3.3 in ΔCt (2^3.3 = 9.8 folds). More importantly, the
amplification slope of the samples was always identical to that
of corresponding templates, suggesting that PCR efficiency
was conserved between the templates and samples. Thus, the
Ct values of drug-treated triplicate samples were subtracted
by the mean Ct values of control samples to calculate ΔCt,
and the fold increase was calculated as 2^(−ΔCt).
RESULTS AND DISCUSSION
Identification of Respondents and Non-Respondents
Prediction of respondents and non-respondents against
specific drug treatment is critically important for clinical trials.
Once non-respondents are identified before drug treatment,
such patients will be excluded from the clinical trial to
improve the chance of success of the study. Figure 1 was an
initial attempt to this field. Mouse monoclonal antibody
IgG1κ against human α/β T cell receptor (TCR) induced
tumor necrosis factor α (TNFα) mRNA in a dose dependent
manner, when antibody was incubated in heparinized human
whole blood for only 2h (Fig. 1A, filled circle). Control mouse
IgG1κ also increased TNFα mRNA (Fig. 1A, open circle),
although the values were much smaller than those of anti-
TCR. Thus, fold increase was calculated by using the same
concentrations of control mouse IgG (Fig. 1B). TCR activa-
tion was known to produce TNFα (9), however, we found
that approximately one third of healthy population increased
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Fig. 2. Ex vivo compound screening. Using three donors (1–3), 50 μl
each of heparinized human whole blood was exposed to various drugs
(all 10 μM in the final concentrations) for 1 h in triplicate, then
stimulated with 10 μg/ml each of anti-TCR (filled circle) or control
IgG (open circle) for an additional 2 h. TNFα (A) and CXCL10 (B)
mRNA were quantified as described above. The y-axis was the Ct,
the cycle of PCR to generate certain amounts of PCR products: the
smaller Ct values mean higher expression, and 1 Ct difference means
double or one half in quantity. Each data point is the mean±SD from
triplicate aliquots of whole blood.
Fig. 3. PHA-induced IL-2 mRNA expression in human whole blood. A Blood samples were stimulated with various concentrations of
phytohemagglutinin-P (PHA) or control (PBS) for 1 h, then IL-2 (filled circle) and β-actin (filled triangle) mRNA were quantified using
TaqMan as described in the Methods. B Blood samples were pretreated with 50–400 nM of CsA (filled circle)o r5 –40 nM of FK506 (open
triangle) for 1 h, then stimulated with 30 μg/ml of PHA or control PBS at 37°C for another 1 h. The %Control was calculated by using the
values of PBS (no PHA) and PHA (no inhibitor) as 0 and 100%, respectively, for each individual. C The IC50 of both CsA (y-axis) and FK506
(x-axis) was plotted. Each data point is the mean±SD (A) or mean (B, C) from each individual. The regression line, r
2, and p value are shown
in the subpanel C.
1118 Mitsuhashi, et al.TNFα mRNA, whereas remaining two thirds failed to respond,
even the highest concentrations of antibodies (10μg/ml) were
used (Fig. 1B). The y-axis of Fig. 1A and B is different, because
the control values were solvent (PBS) (A) and control IgG at
each time point (B), respectively. This is the first report showing
ex vivo respondents and non-respondents for TCR-mediated
TNFα mRNA induction, although its clinical implication is not
yet characterized.
TCR is a heterodimer molecule of immunoglobulin-like
α and β chains, and is associated with 4 molecules of CD3
(γ, δ, and 2ɛ), 2 ζ chains, and CD8 (homo- or hetrodimer of α
and β chains) to form the TCR-CD3 complex. TCR α/β
chains are the molecules to recognize the specific structure of
the target to elicit various immunological reactions. Figure 1
was a model system to assess TCR functionality by activating
TCR α/β chains with agonistic anti-TCR antibody. The
components of TCR-CD3 complex have multiple transcript
variants as well as various genetic polymorphisms (10–13).
TCR-CD3 complex is also known to activate various kinases
(14,15), and these kinases have multiple transcript variants
and genetic polymorphisms, too (16). Thus, altered functions
of TCR shown in Fig. 1 may happen by genetic alterations of
any of these genes. Alternatively, non-respondents may have
some inhibitor in plasma. However, it is time consuming,
labor-intensive, and expensive to identify genetic polymor-
phisms of these genes as well as discovery of unknown plasma
factors in each human subject. The identification of functional
respondents and non-respondents under physiological ex vivo
condition may be useful to classify the patient population for
clinical trials of immunomodulatory drugs and vaccines,
where TCR plays a crucial biological function.
Ex Vivo Compound Screening
Drug candidate compounds are usually screened by cell-
free system or cultured cells. Figure 2 is a new concept of ex
vivo screening directly using human whole blood. Each blood
sample was exposed to various drugs 1h prior to anti-TCR
stimulation, then TNFα (Fig. 2A) mRNA was quantified as
described above. Furthermore, additional CXCL10 cytokine
Fig. 4. Drug-induced p21 and PUMA mRNA expression in whole blood from leukemia patients. Peripheral blood samples from 64 years old
male patient with acute myelogenous leukemia (AML) (A) and 53 years old male patient with acute promyeocytic leukemia (APL) (B) were
mixed with various anti-leukemia drugs at 37°C for 4 h, then p21 (open square) and PUMA (filled square) mRNA were quantified using
TaqMan as described in the “Materials and Methods”. The population of leukemic cells was 96 (A) and 94% (B), respectively. Each data point
is the mean±SD from triplicate aliquots of whole blood. Hashed areas are negative with <1.5 fold increase. Drugs used were cytarabine
(AraC), daunorubicin (DNR), mitoxantrone (MIT), aclarubicin (ACR), and etoposide (VP16), idarubicin (IDR), and predonisone (PSL) with
designated dose (in parentheses)i nμM.
1119 Ex Vivo Platform of Drug DevelopmentmRNA was also quantified (Fig. 2B). Blood volume used for
each volunteer was less than 3ml [8 (7 drugs and 1 control) ×
2 (control IgG and anti-TCR) × 3 (triplicate) × 60μl]. The
y-axis was the Ct, the cycle of PCR to generate certain
amounts of PCR products: the smaller Ct values mean higher
expression, and 1 Ct difference means double or one half in
quantity. In order to screen a wide spectrum of compounds,
each donor was treated with different drugs. Three donors
(all respondents) showed different expression levels of TNFα
and CXCL10 mRNA (Fig. 2, open circle), and cilostazol
(Fig. 2A) and rolipram (Fig. 2A,B) decreased the basal
expression levels of these mRNA (Fig. 2, open circle). Anti-
TCR antibody induced TNFα and CXCL10 mRNA (Fig. 2,
filled circle), with the Ct difference approximately 2 (=4 fold
increase) and 4–6 (=16–64 fold increase) for TNFα and
CXCL10 mRNA, respectively, in these 3 donors. However,
cyclosporine (CsA) and tacrolimus (FK506) completely
eliminated the induction of TNFα mRNA (Fig. 2A, filled
circle). Interestingly, additional JAK inhibitor I also inhibited
CXCL10 mRNA induction (Fig. 2B, filled circle). These results
were reasonable, because the effects of cyclosporine (17,18)
and JAK kinase inhibitor (19) were reported previously.
As screening assay, 10μM was used for all drugs in Fig. 2,
because 10μM is a highest achievable blood level for many
drugs. Once candidates are identified, the same assay
platform can be used to draw an IC50 as well as the analysis
of individual-to-individual variations among large number of
healthy adults and appropriate disease patients. When the
compounds are selected for clinical trials, the same assay can
be used to identify respondents from the study subjects as
discussed above. The ex vivo drug screening shown in Fig. 2
will be a valuable tool for drug development, including
various kinase inhibitors for inflammation, autoimmune
diseases, transplantation, etc. The concept of ex vivo drug
screening is expandable beyond anti-TCR-induced TNFα and
CXCL10 mRNA by introducing various other stimulations
and corresponding target mRNA.
Determination of Individually Optimized Doses
Unlike Fig. 1, many drugs show dose dependent reac-
tions, and study subjects will be classified into low- and high-
respondents. For low respondents, drug doses should be
increased to induce appropriate clinical responses, whereas
drug doses should be decreased for high-respondents to
eliminate unwanted side effects. Determination of individu-
ally optimized doses is not only useful for clinical practice as a
tailored medicine, but also applicable to study design of
clinical trials in future. Figure 3 demonstrated an example of
such dose-dependent ex vivo analysis. Phytohemagglutinin-P
(PHA) increased IL2 mRNA in a dose dependent manner
(Fig. 3A, filled circle), whereas control β-actin mRNA was
unchanged (Fig. 3A, filled triangle). Pretreatment with
cyclosporine (CsA) and tacrolimus (FK506) inhibited PHA-
induced IL2 mRNA expression in a dose dependent manner
(Fig. 3B), with an IC50 of 100–450nM and 1–18nM for CsA
and FK, respectively (Fig. 3C). The results were similar to
those reported by other groups (20,21), however, our method
was more practical in terms of blood volume, throughput, and
reproducibility.
The range of IC50 varies 5–20 folds, suggesting that drug
doses may be determined individually by assessing IC50 for
each patient. The practice of therapeutic drug monitoring
Fig. 6. Screening of tumor necrosis factor superfamily (TNFSF)
mRNA. Blood samples were stimulated with either 100 μg/ml each of
PHA (A, n=12) or convanavalin A (B, n=3), 10 μg/ml lipopolysac-
charide (LPS)( C, n=4), or 200 μg/ml of heat aggregated human IgG
(HAG) (D, n=20) at 37°C for 4 h, then all members of TNFSF mRNA
were quantified using SYBRgreen PCR and fold increase was
calculated by using the values of solvent (PBS) as control, as described
in the Methods. The cDNA was diluted 1:4 with water, and used for
PCR. TNFSF10, 11, 18 showed some primer dimers. Each data point is
the mean from triplicate whole blood samples in each individual.
Fig. 5. Bleomycin (BLM)-induced p21 and PUMA mRNA expres-
sion in human whole blood. Blood samples from 18 healthy adult
volunteers were stimulated with 0–10 μM BLM for 4 h, then p21 (A)
and PUMA (B) mRNA were quantified using TaqMan as described
in the “Materials and Methods”. Each data point is the mean from
triplicate whole blood samples in each individual. Hashed areas are
considered as negative response with <1.5 fold increase.
1120 Mitsuhashi, et al.(TDM) was introduced many years ago when new technolo-
gies allowed us to determine the levels of drug concentrations
in serum or plasma. Functional variations determined by the
ex vivo analysis will be a new addition to TDM in future.
Although high respondents to CsA were also high
respondents to FK506, variation existed among individuals
(Fig. 3C). This may indicate the possibility of drug preference
between CsA and FK506. This is reasonable because CsA
and FK506 are acting against different molecular targets
[cyclophilin for CsA (22) and FK506 binding protein for
FK506 (23)], although both inhibit calcineurin.
Drug-to-Drug Comparison
When a new drug is introduced to the market, it is
required to show advantages of such drug against existing
ones, if similar drugs are available. Using whole blood
samples from leukemia patients, where more than 96%
Fig. 8. Effects of various dietary supplements on PHA-induced IL2 mRNA expression. Blood samples from seven healthy adult volunteers
(Donor 1–7) were preincubated with various dietary supplements for 1 h, then PHA (100 μg/ml)-induced IL2 mRNA was quantitated as
described in the “Materials and Methods” and Fig. 3. Each symbol represents the Ct values of control (PBS) (open circle, filled circle) or PHA
stimulation (open triangle, filled triangle), respectively. Each data point is the mean±SD from triplicate aliquots of whole blood. Filled circle and
filled triangle indicated statistical significance <0.05. 1 Control, 2 vitamin A (0.1 μM), 3 vitamin C (10 μg/ml), 4 epigallocatechin gallate (green
tea) (10 μM), 5 genistein (soybean) (2 μM), and 6 curcumin (turmeric) (200 nM).
Fig. 7. Effects of fucoidan ingestion on HAG-induced TNFSF15 and IL8 mRNA expression. A Blood samples were stimulated with various
concentrations of HAG, then TNFSF15 (open circle) or IL8 (filled triangle) were quantified. Each data point is the mean from triplicate
aliquots of whole blood from a single individual. B, C Blood samples were obtained before and 4 h after 50 ml of fuoidan (2,550 mg) ingestion.
These samples were then stimulated with 100 μg/ml of HAG at 37°C for 4 h, and TNFSF15 (B) and IL8 (C) mRNA were quantified using
SYBRgreen PCR as described in the Methods. Each data point is the mean from each individual. In C, each symbol (open circle, open triangle,
open square, and open diamond) represents the same individual tested two to four times with more than 1 week interval.
1121 Ex Vivo Platform of Drug Development(Fig. 4A) or 94% (Fig. 4B) of leukocytes were leukemic,
drug-induced p21 (Fig. 4, open square) and PUMA (Fig. 4,
filled square) mRNA were measured. The p21 (cyclin-
dependent kinase inhibitor 1A, CDKN1A) (24) and PUMA
(p53 upregulated modulator of apoptosis) (25–27)w e r e
known to be induced transcriptionally by p53 when DNA
was damaged by genotoxic drugs. In other words, p21 is
responsible for cell cycle arrest, and PUMA is pro-apoptotic.
Thus, the analysis of these two genes may correspond to
cytostatic and cytocidal effects of drugs, similar to bacterio-
static and bacteriocidal effects of antibiotics. As shown in
Fig. 4, preferable drugs were different between these patients
(MIT, ACR, VP16 for A, DNR, VP16, IDR for B) in ex vivo
condition. The comparison of experimental drug candidates
with clinically available drugs in whole blood under physio-
logical ex vivo condition will be an interesting model for the
development of anti-leukemia drugs. Since the number of
leukocytes is high in leukemia in many cases, many drug
candidates can be analyzed simultaneously. Moreover, as
shown in Fig. 4, where the effect of predonisone (PSL) were
also analyzed, different class of drug candidates can be
assessed whether they boost the effects of existing drugs, or
reverse drug resistance.
Assessment of Leukocyte Toxicity
Although leukocyte toxicity is not a major problem for
anti-leukemia drugs, it becomes a huge problem for anti-
cancer drugs for solid tumors, because it sometimes
becomes fatal. Unfortunately, this side effect is unpredict-
able. Figure 5 is an example, where 0–10μM bleomycin
(BLM) were used to stimulate whole blood and p21 and
PUMA mRNA were quantified under the identical condition
to that of Fig. 4. As shown in Fig. 5, the responses were dose
dependent for both p21 and PUMA, and all individuals
showed more than 1.9 fold increase at 10μM BLM. Interest-
ingly, approximately half [56% (A) and 44% (B)] of healthy
individuals responded to 0.1μM BLM to induce p21 and
PUMA mRNA, respectively, whereas the other half did not.
Among them, one individual failed to induce both p21 and
PUMA mRNA even at 1μM of BLM. The results of Fig. 5 do
not directly indicate the predictability of leukocyte toxicity,
because toxic BLM is not allowed to be administered to
healthy individuals. However, the existence of p21 and
PUMA respondents at low concentrations of BLM may
provide additional considerations for the development of
chemotherapeutic drugs.
Discovery of Molecular Targets
In Fig. 3, PHA-induced IL-2 mRNA was quantified,
because the system was previously reported (20,21). Then, the
remaining cDNA was further used to screen various mRNA.
Figure 6 illustrates the results of the screening of tumor
necrosis factor superfamily (TNFSF) mRNA. As shown in
Fig. 6A, PHA induced TNFSF2 (=TNFα), 5 (=CD40 ligand),
6 (=Fas ligand), 9, and 14 (=LIGHT, CD258). B-cell
stimulator lectin, concanavalin A (ConA) induced TNFSF2,
6, 9, and 14 mRNA, but not TNFSF5 mRNA (Fig. 6B).
Lipopolysaccharide (LPS), which is known to activate Toll-
like receptor-2 (28) and 4 (29) induced mainly TNFSF2
mRNA (Fig. 6C). Moreover, the classic model of immune
complex, heat aggregated IgG (HAG) (30) induced different
classes of TNFSF, such as TNFSF8 (CD30 ligand, CD153)
and 15 (=TL1A) as well as TNFSF2, 9 and 18 in some cases
(Fig. 6D). Since human genome and mRNA sequences are
available, new molecular targets can be discovered by ex vivo
screening as shown in Fig. 6.
HAG-induced TNFSF mRNA may be an interesting
clinical research model of antibody medicines, because
therapeutic antibodies will form immune complexes in the
body by binding to the target molecules. The immune
complexes are known to activate IgG Fc receptors (FcγR),
and FcγR-mediated functions are consisted of numerous
variants, such as 4 subclasses of Fc portions of IgG (IgG1–
4), multiple classes of FcγR [FcγRIa, b, c (=CD64), FcγRIIa,
b, c (=CD32), and FcγRIIIa and b (=CD16)], different
subsets of FcγR-bearing leukocytes, and various inducible
cytokines. Moreover, these proteins have multiple transcript
variants as well as various genetic polymorphisms (31,32). As
shown in Fig. 6D, HAG showed respondents and non-
respondents for each of TNFSF mRNA, and these variations
may happen at any of these genes. The individual variations
of ex vivo responses shown in Fig. 6D may be a predictable
marker for the efficacy and toxicity of antibody medicines.
Assessment of Acute Action of Dietary Supplements
Although various dietary supplements are used widely,
the scientific evidence for their efficacy is not well established.
One of problems of dietary supplement research is the lack of
scientific and quantitative methods to assess acute actions,
because chronic effects are difficult to interpret. Since dietary
supplements are freely available, we can analyze the effects of
dietary supplements before and after ingestion for each
individual. Figure 7 was an example of fucoidan, the sea weed
extract used widely in Japan. We collected blood samples
before and 4 hours after ingestion of 50ml of fuoidan
(2,550mg), and analyzed the changes of HAG-induced
TNFSF15 and IL8 mRNA induction. As shown in Fig. 7A,
HAG (100μg/ml) induced TNFSF15 and IL8 in a dose
dependent manner. Although the levels of HAG-induced
TNFSF15 mRNA expression were unchanged between these
2 samples (Fig. 7B), the levels of HAG-induced IL8 mRNA
was significantly reduced after fucoidan ingestion (Fig. 7C).
The same individuals were tested two to four times (Fig. 7C,
each symbol represents the same individual), however, the
effects of fucoidan was confirmed every time. Although the
biological and clinical meanings of the results are not known at
this time, it is surprising to find such significant effects within
4h of ingestion. The ex vivo assay will be sensitive enough to
analyze the efficacy of dietary supplements in each individual.
Characterization of Respondents and Non-respondents
for Dietary Supplements
Dietary supplements, such as vitamins, polyphenols,
turmeric, etc. are known to induce various biological activities
in cultured cells and animals, and some of activities were
confirmed by subsequent clinical studies. However, the results
of clinical studies are difficult to interpret because of the in-
consistency of the results. If respondents and non-respondents
1122 Mitsuhashi, et al.exist, and the later population is much larger than the former,
the standard method of double blind clinical trials is no longer
useful. Since the blood levels of active ingredients of dietary
supplements were well characterized, simulation will be
theoretically possible by incubating whole blood with pure
ingredients at designated blood levels. In Fig. 8, human whole
blood was pretreated with various ingredients 1 hour prior to
PHA-induced IL2 mRNA expression analysis. The concen-
trations of these ingredients used in Fig. 8 (0.1 μM vitamin A,
10 μg/ml vitamin C, 10 μM epigallocatechin gallate (green tea),
2 μM genistein (soybean), and 200 nM curcumin (turmeric)
were achievable blood levels according to various literature.
The effects of dietary supplements were much weaker than
active drugs as shown in Figs. 2 and 3, however, some showed
significant influences on the basal expression levels of IL2
mRNA as well as PHA-induced IL2 mRNA expression
(Fig. 8, filles circle, filled triangle). However, such effects
were not identified for all individuals. For example, vitamin A
enhanced PHA-induced IL2 mRNA expression in four
(Donor 1, 2, 5, 7) out of seven individuals, whereas vitamin
C inhibited the reaction in three cases (Donor 3, 4, 6)
(Fig. 8B, filled triangle). The ex vivo simulation was sensitive
enough to identify respondents and non-respondents for
dietary supplements, although biological and clinical mean-
ings are not clear at this time. However, identification of
individual variation will be a useful tool for the clinical studies
of diet and dietary supplements in future.
CONCLUSIONS
The ex vivo analysis is a new concept we introduced
recently by using an mRNA quantification platform we
developed (1,2). In order to explore the possibility of ex
vivo assay, various applications are demonstrated in this
study. Although mRNA expression does not always corre-
spond to protein synthesis and subsequent biological and
clinical outcomes, identification of appropriate mRNA induc-
tion in each individual will be a useful information for the
development of drugs and dietary supplements. Since 450 ml
of blood can be obtained from a single individual (450 ml is a
unit of blood donation for transfusion in the US), and the ex
vivo assay uses as little as 50 μl per reaction (150 μli n
triplicate for each drug), as many as 3,000 drug compounds
can be screened. Thus, we believe that the proposed ex vivo
assay will be a new addition to pharmaceutical and dietary
supplement research.
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